In vitro additive effects of dalbavancin and rifampicin against biofilm of Staphylococcus aureus

被引:18
作者
Jacob, Benjamin [1 ]
Makarewicz, Oliwia [2 ]
Hartung, Anita [2 ]
Brodt, Steffen [1 ]
Roehner, Eric [1 ]
Matziolis, Georg [1 ]
机构
[1] Univ Hosp Jena, Campus Eisenberg,Klosterlausnitzer Str 81, D-07607 Eisenberg, Germany
[2] Jena Univ Hosp, Inst Infect Dis & Infect Control, D-07747 Jena, Germany
关键词
VANCOMYCIN; INFECTION; COMBINATION; THERAPY; PROFILE; BONE; SKIN;
D O I
10.1038/s41598-021-02709-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Dalbavancin is a novel glycopeptide antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). It is characterized by a potent activity against numerous Gram-positive pathogens, a long elimination half-life and a favorable safety profile. Most recently, its application for the treatment of periprosthetic joint infections (PJIs) was introduced. The aim of this study was to proof our hypothesis, that dalbavancin shows superior efficacy against staphylococcal biofilms on polyethylene (PE) disk devices compared with vancomycin and additive behavior in combination with rifampicin. Staphylococcus aureus biofilms were formed on PE disk devices for 96 h and subsequently treated with dalbavancin, vancomycin, rifampicin and dalbavancin-rifampicin combination at different concentrations. Quantification of antibacterial activity was determined by counting colony forming units (CFU/ml) after sonification of the PE, serial dilution of the bacterial suspension and plating on agar-plates. Biofilms were additionally life/dead-stained and visualized using fluorescence microscopy. Dalbavancin presented superior anti-biofilm activity compared to vancomycin. Additive effects of the combination dalbavancin and rifampicin were registered. Dalbavancin combined with rifampicin presents promising anti-biofilm activity characteristics in vitro. Further in vivo studies are necessary to establish recommendations for the general use of dalbavancin in the treatment of PJIs.
引用
收藏
页数:5
相关论文
共 23 条
  • [1] Reduced Vancomycin Susceptibility in an In Vitro Catheter-Related Biofilm Model Correlates with Poor Therapeutic Outcomes in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus
    Abdelhady, Wessam
    Bayer, Arnold S.
    Seidl, Kati
    Nast, Cynthia C.
    Kiedrowski, Megan R.
    Horswill, Alexander R.
    Yeaman, Michael R.
    Xiong, Yan Q.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (03) : 1447 - 1454
  • [2] Organism Profile in Periprosthetic Joint Infection: Pathogens Differ at Two Arthroplasty Infection Referral Centers in Europe and in the United States
    Aggarwal, Vinay K.
    Bakhshi, Hooman
    Ecker, Niklas Unter
    Parvizi, Javad
    Gehrke, Thorsten
    Kendoff, Daniel
    [J]. JOURNAL OF KNEE SURGERY, 2014, 27 (05) : 399 - 405
  • [3] Anderson VR, 2008, DRUGS, V68, P639, DOI 10.2165/00003495-200868050-00006
  • [4] Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model
    Baldoni, Daniela
    Tafin, Ulrika Furustrand
    Aeppli, Sandrine
    Angevaare, Eline
    Oliva, Alessandra
    Haschke, Manuel
    Zimmerli, Werner
    Trampuz, Andrej
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 (03) : 220 - 225
  • [5] Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection
    Boucher, Helen W.
    Wilcox, Mark
    Talbot, George H.
    Puttagunta, Sailaja
    Das, Anita F.
    Dunne, Michael W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (23) : 2169 - 2179
  • [6] Martín LB, 2019, REV ESP QUIM, V32, P532
  • [7] Structural mechanism for rifampicin inhibition of bacterial RNA polymerase
    Campbell, EA
    Korzheva, N
    Mustaev, A
    Murakami, K
    Nair, S
    Goldfarb, A
    Darst, SA
    [J]. CELL, 2001, 104 (06) : 901 - 912
  • [8] Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo
    Darouiche, RO
    Mansouri, MD
    [J]. JOURNAL OF INFECTION, 2005, 50 (03) : 206 - 209
  • [9] In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times
    Di Pilato, Vincenzo
    Ceccherini, Federica
    Sennati, Samanta
    D'Agostino, Federico
    Arena, Fabio
    D'Atanasio, Noemi
    Di Giorgio, Francesco Paolo
    Tongiani, Serena
    Pallecchi, Lucia
    Rossolini, Gian Maria
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2020, 96 (02)
  • [10] Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue
    Dunne, Michael W.
    Puttagunta, Sailaja
    Sprenger, Craig R.
    Rubino, Chris
    Van Wart, Scott
    Baldassarre, James
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (04) : 1849 - 1855